Literature DB >> 18469827

Paul Ehrlich's magic bullet concept: 100 years of progress.

Klaus Strebhardt1, Axel Ullrich.   

Abstract

Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469827     DOI: 10.1038/nrc2394

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  271 in total

1.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Authors:  Nagesh Kolishetti; Shanta Dhar; Pedro M Valencia; Lucy Q Lin; Rohit Karnik; Stephen J Lippard; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 2.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

3.  Optimization of magnetic nanoparticle-assisted lentiviral gene transfer.

Authors:  Christina Trueck; Katrin Zimmermann; Olga Mykhaylyk; Martina Anton; Sarah Vosen; Daniela Wenzel; Bernd K Fleischmann; Alexander Pfeifer
Journal:  Pharm Res       Date:  2012-01-25       Impact factor: 4.200

4.  Stapled peptides: Magic bullets in nature's arsenal.

Authors:  Joshua A Kritzer
Journal:  Nat Chem Biol       Date:  2010-08       Impact factor: 15.040

5.  AACR Cancer Progress Report 2015.

Authors:  José Baselga; Nina Bhardwaj; Lewis C Cantley; Ronald DeMatteo; Raymond N DuBois; Margaret Foti; Susan M Gapstur; William C Hahn; Lee J Helman; Roy A Jensen; Electra D Paskett; Theodore S Lawrence; Stuart G Lutzker; Eva Szabo
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

Review 6.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

Review 7.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

Review 8.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 9.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Undesired versus designed enzymatic cleavage of linkers for liver targeting.

Authors:  Srinivas R Chirapu; Jonathan N Bauman; Heather Eng; Theunis C Goosen; Timothy J Strelevitz; Subhash C Sinha; Robert L Dow; M G Finn
Journal:  Bioorg Med Chem Lett       Date:  2014-01-08       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.